RS52423B - New crystalline form v of agometaline, the process for its preparatin and the pharmaceutical compositions containing it - Google Patents

New crystalline form v of agometaline, the process for its preparatin and the pharmaceutical compositions containing it

Info

Publication number
RS52423B
RS52423B RS20120327A RSP20120327A RS52423B RS 52423 B RS52423 B RS 52423B RS 20120327 A RS20120327 A RS 20120327A RS P20120327 A RSP20120327 A RS P20120327A RS 52423 B RS52423 B RS 52423B
Authority
RS
Serbia
Prior art keywords
crystalline form
agometaline
preparatin
pharmaceutical compositions
compositions containing
Prior art date
Application number
RS20120327A
Other languages
Serbian (sr)
Inventor
Jean-Claude Souvie
Gérard Coquerel
Julie Linol
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36581629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52423(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of RS52423B publication Critical patent/RS52423B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Kristalni oblik V agomelatina formule (I) :naznačen time što je dijagram difrakcije X zraka na dobijenom prašku kako sledi, a što je mereno na difraktometru Siemens D5005 (bakarna antikatoda) i izraženo kao među-mrežna udaljenost d, ugao Bragg 2 teta i, relativni intenzitet (izražen u procentima u odnosu na najintenzivniju prugu):2-teta (°) exp. d (A) exp. Intenzitet (%)9,84 8,979 1712,40 7,134 1513,31 6,646 co15,14 5,848 1815,98 5,543 1816,62 5,329 1917,95 4,939 10018,88 4,697 6520,49 4,332 2420,99 4,228 3423,07 3,852 3923,44 3,792 3624,28 3,663 5825,10 3,545 1926,02 3,422 1526,82 3,322 1927,51 3,239 16Prijava sadrži još 5 patentnih zahteva.Crystalline form V of agomelatine of formula (I): characterized in that the X-ray diffraction pattern on the obtained powder is as follows, measured on a Siemens D5005 diffractometer (copper anticathode) and expressed as inter-network distance d, Bragg 2 theta angle i, relative intensity (expressed as a percentage of the most intense band): 2-theta (°) exp. d (A) exp. Intensity (%) 9,84 8,979 1712,40 7,134 1513,31 6,646 co15,14 5,848 1815,98 5,543 1816,62 5,329 1917,95 4,939 10018,88 4,697 6520,49 4,332 2420,99 4,228 3423,07 3,852 3923, 44 3,792 3624,28 3,663 5825,10 3,545 1926,02 3,422 1526,82 3,322 1927,51 3,239 16The application contains 5 more claims.

RS20120327A 2005-08-03 2006-08-02 New crystalline form v of agometaline, the process for its preparatin and the pharmaceutical compositions containing it RS52423B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508278A FR2889523B1 (en) 2005-08-03 2005-08-03 NOVEL CRYSTALLINE FORM V OF AGOMELATIN, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Publications (1)

Publication Number Publication Date
RS52423B true RS52423B (en) 2013-02-28

Family

ID=36581629

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120327A RS52423B (en) 2005-08-03 2006-08-02 New crystalline form v of agometaline, the process for its preparatin and the pharmaceutical compositions containing it

Country Status (38)

Country Link
EP (2) EP1752443B1 (en)
JP (1) JP4575337B2 (en)
CN (1) CN100448843C (en)
AP (1) AP2486A (en)
AR (1) AR057715A1 (en)
AU (1) AU2006203342B2 (en)
BR (1) BRPI0603059A (en)
CA (1) CA2555115C (en)
CR (1) CR8529A (en)
CU (1) CU20060153A7 (en)
CY (1) CY1113011T1 (en)
DK (1) DK1752443T3 (en)
EA (1) EA011030B1 (en)
EC (1) ECSP066715A (en)
ES (1) ES2391406T3 (en)
FR (1) FR2889523B1 (en)
GT (1) GT200600346A (en)
HK (1) HK1098128A1 (en)
HR (1) HRP20120779T1 (en)
IL (1) IL177173A (en)
JO (1) JO2793B1 (en)
MA (1) MA28451B1 (en)
ME (1) ME02026B (en)
MX (1) MXPA06008789A (en)
MY (1) MY139902A (en)
NO (1) NO336967B1 (en)
NZ (1) NZ548864A (en)
PE (1) PE20070365A1 (en)
PL (1) PL1752443T3 (en)
PT (1) PT1752443E (en)
RS (1) RS52423B (en)
SA (1) SA06270255B1 (en)
SG (1) SG130110A1 (en)
SI (1) SI1752443T1 (en)
TW (1) TWI359128B (en)
UA (1) UA83720C2 (en)
WO (1) WO2007015004A2 (en)
ZA (1) ZA200606453B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2934856B1 (en) * 2008-08-05 2010-08-13 Servier Lab NEW PROCESS FOR OBTAINING THE V-CRYSTALLINE FORM OF AGOMELATIN
CN101481321B (en) * 2009-02-27 2012-04-18 上海医药工业研究院 Agomelatine halogen hydride complex and preparation thereof
CN101585779B (en) * 2009-03-10 2014-04-02 上海医药工业研究院 New crystal form of Agomelatine, preparation method and use thereof
WO2011006387A1 (en) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 Process for preparing agomelatine, crystals of agomelatine and preparing process thereof
CN102001959B (en) * 2009-09-01 2014-07-02 北京本草天源药物研究院 Medicinal crystal as well as preparation method and application thereof
CN102050755B (en) * 2009-10-29 2014-11-05 重庆医药工业研究院有限责任公司 Novel agomelatine crystal forms and preparation methods of agomelatine crystal forms
CN101781226B (en) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 Agomelatine and medicine composition thereof
EP2580183B1 (en) 2010-06-10 2014-07-23 Gador S.A. New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide
CN102000583B (en) * 2010-11-18 2012-08-15 烟台万华聚氨酯股份有限公司 Catalyst for preparing chlorine by oxidizing hydrogen chloride and preparation method thereof
CN102690210A (en) * 2011-03-23 2012-09-26 上海医药工业研究院 Novel crystal form VII of agomelatine, preparation method and application thereof and pharmaceutical composition containing the same
CN102690209A (en) * 2011-03-23 2012-09-26 上海医药工业研究院 Mixed crystal of agomelatine (form-VIII), preparation method and application thereof and pharmaceutical composition containing the same
US9238621B2 (en) * 2011-06-02 2016-01-19 Chinoin Zrt Processes for the preparation of prostaglandin amides
FR2978916B1 (en) 2011-08-10 2013-07-26 Servier Lab SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN
EP2771312B1 (en) 2011-11-30 2017-05-31 ratiopharm GmbH Agomelatine-urea complex and crystalline forms thereof
CZ2012108A3 (en) 2012-02-15 2013-02-27 Zentiva Ks A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine
CN103360275B (en) * 2012-03-30 2015-04-22 上海创诺制药有限公司 Method for preparing agomelatine I-type crystal
WO2014096373A1 (en) 2012-12-21 2014-06-26 Laboratorios Lesvi, S. L. Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
FR3001894A1 (en) 2013-02-08 2014-08-15 Servier Lab SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
HUE036989T2 (en) 2013-06-06 2018-08-28 Zentiva Ks Agomelatine formulations comprising agomelatine in the form of co-crystals
CZ2013621A3 (en) 2013-08-13 2015-02-25 Zentiva, K.S. Agomelatine thermodynamically stable congealed solution for use in pharmaceutical formulation
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
FR3033131B1 (en) 2015-02-26 2017-11-17 Servitronique SLIDE FOR ITS SLIDING ADJUSTMENT SYSTEMS AND ASSEMBLY METHOD
ES2959460T3 (en) 2015-03-31 2024-02-26 Fis Fabbrica Italiana Sintetici Spa solid form of agomelatine
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof
EP3466923A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Process for the preparation of agomelatine in crystalline form
CN113952323A (en) * 2021-12-10 2022-01-21 李甜 Application of agomelatine in inhibition of Ube2c protein expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (en) * 1990-02-27 1993-12-31 Adir Cie NOVEL DERIVATIVES WITH NAPHTHALENIC STRUCTURE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2866336B1 (en) * 2004-02-13 2006-03-24 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF (7-METHOXY-3,4-DIHYDRO-1-NAPHTHALENYL) ACETONITRILE AND APPLICATION TO THE SYNTHESIS OF AGOMELATIN
FR2866335B1 (en) * 2004-02-13 2006-05-26 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF AGOMELATIN

Also Published As

Publication number Publication date
MA28451B1 (en) 2007-03-01
EP1752443A1 (en) 2007-02-14
ECSP066715A (en) 2007-03-29
MXPA06008789A (en) 2007-02-02
CU20060153A7 (en) 2012-04-15
MY139902A (en) 2009-11-30
ME02026B (en) 2012-11-06
PT1752443E (en) 2012-07-25
DK1752443T3 (en) 2012-10-22
EP2277857A2 (en) 2011-01-26
EA200601273A1 (en) 2007-02-27
CN100448843C (en) 2009-01-07
JP2007056017A (en) 2007-03-08
SI1752443T1 (en) 2012-10-30
CA2555115A1 (en) 2007-02-03
TW200736199A (en) 2007-10-01
UA83720C2 (en) 2008-08-11
FR2889523A1 (en) 2007-02-09
AR057715A1 (en) 2007-12-12
SG130110A1 (en) 2007-03-20
SA06270255B1 (en) 2010-06-13
AP2006003695A0 (en) 2006-08-31
AP2486A (en) 2012-10-03
NO336967B1 (en) 2015-12-07
HRP20120779T1 (en) 2012-10-31
NZ548864A (en) 2008-03-28
JO2793B1 (en) 2014-03-15
PL1752443T3 (en) 2012-11-30
EP1752443B1 (en) 2012-07-11
CA2555115C (en) 2013-12-10
EA011030B1 (en) 2008-12-30
CN1907958A (en) 2007-02-07
CY1113011T1 (en) 2016-04-13
NO20063517L (en) 2007-02-05
BRPI0603059A (en) 2007-08-14
AU2006203342B2 (en) 2012-07-19
WO2007015004A3 (en) 2007-03-22
HK1098128A1 (en) 2007-07-13
JP4575337B2 (en) 2010-11-04
EP2277857A3 (en) 2011-06-01
WO2007015004A2 (en) 2007-02-08
TWI359128B (en) 2012-03-01
PE20070365A1 (en) 2007-06-02
IL177173A (en) 2011-10-31
ES2391406T3 (en) 2012-11-26
GT200600346A (en) 2007-02-28
ZA200606453B (en) 2007-12-27
CR8529A (en) 2006-12-07
FR2889523B1 (en) 2007-12-28
AU2006203342A1 (en) 2007-02-22
IL177173A0 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
RS52423B (en) New crystalline form v of agometaline, the process for its preparatin and the pharmaceutical compositions containing it
MY148319A (en) New crystalline form vi of agomelatine, a process for its preparation and pharmaceutical compositions containing it
RS50915B (en) α CRYSTALLINE FORM OF PERINDOPRIL TERT-BUTYLAMINE SALT
CO5780132A1 (en) NEW CRYSTALLINE AND AGOMELATINE FORM, PREPARATION PREPARATION AND THE COMPOSITIONS CONTAINING THEM
TW200716511A (en) New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
MY162033A (en) New process for the synthesis of agomelatine
AR046124A1 (en) POLYMORPHIC FORM OF THE N - [(R) -2,3-DIHYDROXIPROPOXI] -3,4 DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) BENZAMIDA; PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS
RS51621B (en) Novel gamma crystalline form of perindopril tertbutylamine salt, preparation method and pharmaceutical compositions containing same
RS50600B (en) CRYSTALLINE FORM GAMMA-d OF THE CHLORHYDRATE OF IVABRADINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CNTAINING IT
MY142270A (en) New process for the synthesis of (7-methoxy-1-naphthyl)acetonitrile and application in the synthesis of agomelatine
MY143266A (en) New process for synthesizing (7-methoxy-3,4-dihydro-1-naphthalenyl)acetonitrile and its application in the synthesis of agomelatine
BRPI0603074A (en) crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing
RU2004114263A (en) Thiazole derivatives having antagonistic agonistic or partially agonistic CB1 activity
RS50661B (en) Crystalline form beta of the chlorhydrate of ivabradine, process for its preparation and pharmaceutical composition containing it
RS50599B (en) Crystalline form beta-d of the chlorhydrate of ivabradine, process for its preparation and pharmaceutical composition containing it
RS54754B1 (en) Crystalline form of the arginine salt of perindopril, process for preparing it, and pharmaceutical compositions comprising it
TW200719897A (en) Diarylsulfone sulfonamides and use thereof
CA2508824A1 (en) Alpha crystalline form of strontium ranelate, its preparation process, and the pharmaceutical compositions that contain it
JO2992B1 (en) New process for the synthesis of (7-methoxy - 1- naphthyl) acetonitrile and application in the synthesis of agomelatine
RS51431B (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
MY144746A (en) Process for the preparation of agomelatine
RS53001B (en) Delta crystalline form of the arginine salt of perindopril, a process for its preparation, and paharmaceutical compositions containing it
MY140089A (en) Process for synthesizing (7-methoxy-1-naphthyl) acetonitrile and its application in the synthesis of agomelatine
HRP20110712T1 (en) New method for obtaining the crystalline form v of agomelatine
MX344965B (en) Preparation of (r)- and (s)-n-(3, 4-difluoro-2-(2-fluoro-4-iodoph enylamino)--6-methoxyphenyl) -1- (2, 3-dihydroxypropyl)cyclopropa ne-1-sulfonamide and protected derivatives thereof.